SCHEMBL2431263

SCHEMBL2431263

Cc1noc(NC(=O)N2CCC3(CC2)CC(c2cccc(Cl)c2)CO3)c1C

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 3/20 0.41
EDNRB P24530 1/20 0.38
EDNRA P25101 1/20 0.38
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
NPY5R Q15761 1/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
HSD11B1 P28845 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.35
RECQL P46063 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
EPHX2 P34913 2/20 0.35
ENPP2 Q13822 2/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
GRIN2B Q13224 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12295576 0.91 MGLL (0.42) MGLLEDNRAALDH1A1CYP3A4CYP2D6
SCHEMBL2429995 0.91 MGLL (0.38) MGLLEDNRBEDNRAKMT2AMEN1
SCHEMBL2428284 0.91 MGLL (0.38) MGLLEDNRBEDNRAKMT2AMEN1
SCHEMBL2434246 0.91 MGLL (0.38) MGLLEDNRBEDNRAKMT2AMEN1
SCHEMBL2430263 0.89 MEN1 (0.39) MGLLEDNRBEDNRAKMT2AMEN1
SCHEMBL2423710 0.88 P2RY1 (0.40) MGLLEPHX2MAPT
SCHEMBL2341595 0.87 CYP3A4 (0.42) MGLLEDNRBEDNRAKMT2AMEN1
SCHEMBL2429562 0.87 MGLL (0.44) MGLLKMT2AMEN1TRPM8RECQL
SCHEMBL2425659 0.87 MGLL (0.44) MGLLKMT2AMEN1TRPM8RECQL
SCHEMBL12295606 0.87 MGLL (0.39) MGLLEDNRBEDNRAALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2367830-A1 1-OXA-8-AZASPIRO [4, 5] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS Pfizer Inc. (US) 2011-09-28 EP claimed
US-20110230493-A1 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors PFIZER INC. 2011-09-22 US claimed
WO-2010058318-A1 1-OXA-8-AZASPIRO [4, 5 ] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS PFIZER INC. (US) 2010-05-27 WO claimed
US-20110230493-A1 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors PFIZER INC. 2011-09-22 US disclosed
US-20110230493-A1 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors PFIZER INC. 2011-09-22 US disclosed
US-20110230493-A1 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors PFIZER INC. 2011-09-22 US disclosed
WO-2010058318-A1 1-OXA-8-AZASPIRO [4, 5 ] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS PFIZER INC. (US) 2010-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230493-A1 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors FAAH, FAAH2, FFAR1 MGLL 246/4885EDNRB 270/4885EDNRA 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.